Replies to post #389009 on Amarin Corp Plc (AMRN)

[IgnoranceIsBliss]

You are so right dude

Let’s hope Bhatt has been working on MOA behind the scenes and surprises us

[ralphey]

So its NOT The science but rather management that is the issue . Hmmm seems I have heard that somewhere before on this board but I will let you in on a little super secret. The scammers are upset because we are now shorting and they are not the only ones making money, however, as more people catch on eventually there will be nothing left to short and no more scamming, then they will need to move to a new company.

[Whalatane]

Another study VALIDATING the Reduce -It trial changes everything .
The Cardiologists I know want independent confirmation that high dose EPA lowers CV event risk

Statins had numerous trials confirming risk reduction… look it up

Dr Taub will present the RESPECT EPA trial . This is no
small thing
Dr Taub is a rising star .. especially for conference presentations .
I doubt if she would agree to present unless she felt it was a well run trial that would influence prescribing activities.

So it’s IMHO a big deal for AMRN

Hopefully RESPECT shows at least a stat sig risk reduction of at least 15 %

IF the RR is 15 % will a p value of say .01 … then that would imply a higher RR in a US R-IT profile population on 4 gms of Vascepa ( bigger jump in serum EPA levels )

15 % RR in RESPECT EPA is in my mind a 20% plus RR in a similar secondarily prevention US population

So we need RESPECT EPA to succeed

Kiwi

[CaptBeer]

MOA? "It's the EPA Stupid." (not you), I've said it a thousand times. So, has Bhatt, Mason, Budoff, Toth, Libby etc.

[Bouf]

Yup, best summary of current state of play I have seen.

Thanks T.

[RobinF]

Agree!
I am not a doctor or scientist but a heart patient with a very curious mind and interest in researching my condition. One thing I come across frequently in my research is the role of destructive Reactive Oxygen Species in the progression of heart disorders. I wonder if IPE somehow interferes with/inhibits the action of these ROS to stop the progression of the damage.

[Meowza]

Big money doesn't accept the fact that "it just works".

yet Big Money uses precisely that premise to "expedite" testing when it comes to their candidate therapies. Amarin doesn't need MOA, proprietary pending alternatives do.

dietary supplement realm

P3 success, try again.

[ilovetech]

I don't believe Amarin was ever conceived to be GIA company. However, It saw becoming a high valued acquisition once the company proved Icosapent Ethyl was in fact a very effective treatment as a new SOC. IMO, it doesn't matter how well Amarin shapes the messaging for prescribers, because it won't change the weekly script count. Amrn's current mission is to secure ROW buy-in, which takes a lot of time for any drug, not just EPA. Once the reimbursements are secured, and Amrn is closer to, or launches V2.0, BP knows how to exploit its own resources to shape public opinion. As for MOA, again Amrn has made it on to just about every medical association guidelines list. If Doctors are too lazy mediocre to bother looking, because they need a BP's hammer to come down on their ignorance, so be it.

ILT